Trial Profile
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs AMG 900 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Amgen
- 02 May 2019 Status changed from active, no longer recruiting to completed.
- 07 Jul 2018 Results (n=105) published in the Investigational New Drugs.
- 12 Mar 2018 Planned End Date changed from 1 May 2018 to 1 May 2019.